Cynthia Goodin, APRN
Family · Barbourville, KYNPI 1265820245
Payments from drug & device makers
Across 121 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$304
- Novartis$164
- AbbVie$157
- Biohaven Pharmaceuticals, Inc.$151
- Bayer$146
- AstraZeneca$133
- plus $861 from 18 others
What the payments were for
- Food & beverage$1,915100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $304 |
| Novartis | 8 | $164 |
| AbbVie | 8 | $157 |
| Biohaven Pharmaceuticals, Inc. | 13 | $151 |
| Bayer | 8 | $146 |
| AstraZeneca | 9 | $133 |
| Astellas Pharma US Inc | 8 | $118 |
| Lilly USA, LLC | 8 | $118 |
| Novo Nordisk | 6 | $102 |
| Sanofi-aventis U.S. LLC | 6 | $93 |
| Merck | 5 | $75 |
| Amarin Pharma, Inc. | 4 | $53 |
| GSK | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Medtronic | 2 | $29 |
| Boehringer Ingelheim | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $15 |
| Amgen | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$1,915 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 69 | $74,872 |
| OzempicSemaglutide | 60 | $59,156 |
| LinzessLinaclotide | 64 | $41,128 |
| JardianceEmpagliflozin | 45 | $29,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $25,679 |
| EliquisApixaban | 34 | $24,381 |
| VascepaIcosapent Ethyl | 40 | $15,388 |
| FarxigaDapagliflozin Propanediol | 19 | $14,316 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $13,772 |
| NexlizetBempedoic Acid/Ezetimibe | 27 | $13,238 |
| XareltoRivaroxaban | 15 | $11,712 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $11,287 |
| UbrelvyUbrogepant | 11 | $11,182 |
| Spiriva RespimatTiotropium Bromide | 21 | $10,892 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $7,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $118 | $74,87269 claims |
| Novo NordiskOzempic | $102 | $59,15660 claims |
| AbbVieLinzess, Ubrelvy | $157 | $52,31075 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $25 | $47,99279 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $53 | $30,29945 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $133 | $25,60331 claims |
| PfizerEliquis | $304 | $24,38134 claims |
| Johnson & JohnsonXarelto | $12 | $11,71215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.
Other family in Barbourville
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.